Total Payments
$33,931
2024 Payments
$1,270
Companies
30
Transactions
500
Medicare Patients
886
Medicare Billing
$439,963
Payment Breakdown by Category
Other$25,373 (74.8%)
Food & Beverage$7,777 (22.9%)
Travel$575.03 (1.7%)
Education$205.87 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,373 | 10 | 74.8% |
| Food and Beverage | $7,777 | 482 | 22.9% |
| Travel and Lodging | $575.03 | 1 | 1.7% |
| Education | $205.87 | 7 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $19,115 | 15 | $0 (2019) |
| Grifols USA, LLC | $7,306 | 10 | $0 (2023) |
| GlaxoSmithKline, LLC. | $2,268 | 204 | $0 (2024) |
| GENZYME CORPORATION | $1,430 | 71 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,353 | 56 | $0 (2024) |
| PFIZER INC. | $399.81 | 30 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $207.30 | 12 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $205.67 | 13 | $0 (2024) |
| OptiNose US, Inc. | $202.53 | 9 | $0 (2022) |
| Amgen Inc. | $184.98 | 8 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,270 | 62 | GENZYME CORPORATION ($440.51) |
| 2023 | $1,630 | 91 | GlaxoSmithKline, LLC. ($526.06) |
| 2022 | $2,502 | 77 | Grifols USA, LLC ($1,258) |
| 2021 | $3,771 | 66 | Grifols USA, LLC ($2,800) |
| 2020 | $3,783 | 48 | Grifols USA, LLC ($3,200) |
| 2019 | $1,110 | 82 | GlaxoSmithKline, LLC. ($377.52) |
| 2018 | $9,591 | 35 | Shire North American Group Inc ($9,266) |
| 2017 | $10,275 | 39 | Shire North American Group Inc ($9,796) |
All Payment Transactions
500 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $2.57 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug), BREZTRI | Education | In-kind items and services | $22.52 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Inflammation & Immunology | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Immunology | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Immunology | ||||||
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Immunology | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Respiratory | ||||||
| 10/09/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $16.76 | General |
| Category: Narcoplepsy | ||||||
| 10/01/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Immunology | ||||||
| 09/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: IMMUNOLOGY | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Respiratory | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: RESPIRATORY | ||||||
| 09/20/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $8.87 | General |
| Category: Immunology | ||||||
| 09/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $99.02 | General |
| Category: Immunology | ||||||
| 09/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $3.07 | General |
| Category: RESPIRATORY | ||||||
| 08/28/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: RESPIRATORY | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: RESPIRATORY | ||||||
| 07/31/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: RESPIRATORY | ||||||
| 07/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: IMMUNOLOGY | ||||||
| 07/11/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: IMMUNOLOGY | ||||||
| 07/09/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 261 | 2,074 | $349,918 | $162,142 |
| 2022 | 7 | 204 | 1,534 | $219,513 | $101,612 |
| 2021 | 7 | 212 | 3,080 | $183,827 | $82,548 |
| 2020 | 6 | 209 | 1,726 | $191,017 | $93,662 |
Total Patients
886
Total Services
8,414
Medicare Billing
$439,963
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 11 | 1,140 | $254,941 | $138,744 | 54.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $34,162 | $8,207 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 103 | $25,441 | $7,435 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 28 | $10,164 | $2,913 | 28.7% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 27 | 602 | $11,438 | $2,119 | 18.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $5,460 | $1,361 | 24.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 110 | $7,920 | $1,273 | 16.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 14 | 14 | $392.00 | $89.96 | 22.9% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 12 | 810 | $146,160 | $83,309 | 57.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 66 | 85 | $20,995 | $6,197 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $17,632 | $4,360 | 24.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 32 | 32 | $11,648 | $3,009 | 25.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 21 | $7,623 | $1,878 | 24.6% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 15 | 461 | $8,759 | $1,714 | 19.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 29 | 93 | $6,696 | $1,143 | 17.1% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2021 | 12 | 2,325 | $106,500 | $63,893 | 60.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 40 | 40 | $22,040 | $5,752 | 26.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 62 | 71 | $17,537 | $4,423 | 25.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 30 | 37 | $13,431 | $3,671 | 27.3% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 19 | 509 | $9,671 | $1,966 | 20.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 26 | 26 | $9,464 | $1,924 | 20.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 23 | 72 | $5,184 | $918.74 | 17.7% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2020 | 14 | 630 | $120,780 | $77,382 | 64.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 76 | 104 | $25,596 | $6,160 | 24.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 43 | 43 | $15,613 | $3,439 | 22.0% |
About Dr. Donatella Graffino, MD
Dr. Donatella Graffino, MD is a Allergy healthcare provider based in Cedar Knolls, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1952302192.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donatella Graffino, MD has received a total of $33,931 in payments from pharmaceutical and medical device companies, with $1,270 received in 2024. These payments were reported across 500 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($25,373).
As a Medicare-enrolled provider, Graffino has provided services to 886 Medicare beneficiaries, totaling 8,414 services with total Medicare billing of $439,963. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Location Cedar Knolls, NJ
- Active Since 08/10/2005
- Last Updated 12/24/2007
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1952302192
Products in Payments
- CUVITRU (Biological) $10,017
- CINRYZE (Drug) $9,238
- Xembify (Biological) $7,278
- DUPIXENT (Biological) $1,493
- NUCALA (Biological) $1,075
- TEZSPIRE (Biological) $920.22
- TRELEGY ELLIPTA (Drug) $601.73
- AREXVY (Drug) $341.29
- FASENRA (Drug) $289.66
- EUCRISA (Drug) $269.14
- Xhance (Drug) $202.53
- Gammaplex (Drug) $184.10
- FASENRA (Biological) $158.28
- DUPIXENT (Drug) $137.35
- BREO (Drug) $126.65
- Hizentra (Biological) $111.75
- Odactra (Drug) $105.87
- CUTAQUIG (Biological) $100.17
- Xolair (Biological) $95.45
- CINQAIR (Drug) $87.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.